Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Constitutive metanephric mesenchyme-specific expression of interferon-gamma causes renal dysplasia by regulating Sall1 expression.

Yun K, Hurwitz AA, Perantoni AO.

PLoS One. 2018 May 17;13(5):e0197356. doi: 10.1371/journal.pone.0197356. eCollection 2018.

2.

Redefining cancer immunotherapy-optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27-30, 2015, Ljubljana, Slovenia.

Aptsiauri N, Jewett A, Hurwitz AA, Shurin MR, Umansky V.

Cancer Immunol Immunother. 2016 Jul;65(7):875-83. doi: 10.1007/s00262-016-1795-8. Epub 2016 Jan 25. No abstract available.

PMID:
26810566
3.

An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers.

Prueitt RL, Wallace TA, Glynn SA, Yi M, Tang W, Luo J, Dorsey TH, Stagliano KE, Gillespie JW, Hudson RS, Terunuma A, Shoe JL, Haines DC, Yfantis HG, Han M, Martin DN, Jordan SV, Borin JF, Naslund MJ, Alexander RB, Stephens RM, Loffredo CA, Lee DH, Putluri N, Sreekumar A, Hurwitz AA, Ambs S.

Cancer Res. 2016 Mar 1;76(5):1055-1065. doi: 10.1158/0008-5472.CAN-14-3630. Epub 2015 Dec 30.

4.

CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells.

Zhu Z, Cuss SM, Singh V, Gurusamy D, Shoe JL, Leighty R, Bronte V, Hurwitz AA.

J Immunol. 2015 Oct 1;195(7):3482-9. doi: 10.4049/jimmunol.1401571. Epub 2015 Aug 28.

5.

T cell avidity and tumor immunity: problems and solutions.

Hurwitz AA, Cuss SM, Stagliano KE, Zhu Z.

Cancer Microenviron. 2014 Aug;7(1-2):1-9. doi: 10.1007/s12307-013-0143-1. Epub 2013 Dec 20.

6.

Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22-25 April 2013, Krakow, Poland.

Shurin MR, Umansky V, Malyguine A, Hurwitz AA, Apte RN, Whiteside T, Jewett A, Thanavala Y, Murphy WJ.

Cancer Immunol Immunother. 2014 Jan;63(1):73-80. doi: 10.1007/s00262-013-1501-z. Epub 2013 Nov 24. No abstract available.

PMID:
24271210
7.

Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.

McGray AJ, Hallett R, Bernard D, Swift SL, Zhu Z, Teoderascu F, Vanseggelen H, Hassell JA, Hurwitz AA, Wan Y, Bramson JL.

Mol Ther. 2014 Jan;22(1):206-18. doi: 10.1038/mt.2013.255. Epub 2013 Oct 23.

8.

High-avidity T cells are preferentially tolerized in the tumor microenvironment.

Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA.

Cancer Res. 2013 Jan 15;73(2):595-604. doi: 10.1158/0008-5472.CAN-12-1123. Epub 2012 Nov 30. Retraction in: Cancer Res. 2016 Apr 15;76(8):2491.

9.

MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.

Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S.

Oncogene. 2013 Aug 29;32(35):4139-47. doi: 10.1038/onc.2012.424. Epub 2012 Sep 17.

10.

Isolation of immune cells from primary tumors.

Watkins SK, Zhu Z, Watkins KE, Hurwitz AA.

J Vis Exp. 2012 Jun 16;(64):e3952. doi: 10.3791/3952. Retraction in: J Vis Exp. 2016;(109). doi: 10.3791/5776.

11.
12.

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

Hurwitz AA, Watkins SK.

Cancer Immunol Immunother. 2012 Feb;61(2):289-293. doi: 10.1007/s00262-011-1181-5. Epub 2012 Jan 12. Review.

PMID:
22237887
13.

MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.

Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM, Ambs S.

Nucleic Acids Res. 2012 Apr;40(8):3689-703. doi: 10.1093/nar/gkr1222. Epub 2011 Dec 30.

14.

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA.

J Clin Invest. 2011 Apr;121(4):1361-72. doi: 10.1172/JCI44325. Epub 2011 Mar 23. Retraction in: J Clin Invest. 2015 May;125(5):2179.

15.

Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.

Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ.

J Immunol. 2010 Jul 1;185(1):174-82. doi: 10.4049/jimmunol.0903548. Epub 2010 Jun 4.

16.

Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.

Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA.

J Immunol. 2009 Oct 15;183(8):4848-52. doi: 10.4049/jimmunol.0900848.

17.

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.

Cancer Res. 2009 Aug 1;69(15):6256-64. doi: 10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. Retraction in: Cancer Res. 2016 Apr 15;76(8):2490.

18.

Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.

Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM.

J Immunol. 2009 Apr 1;182(7):4328-38. doi: 10.4049/jimmunol.0800471.

19.

Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Singh V, Ji Q, Feigenbaum L, Leighty RM, Hurwitz AA.

J Immunother. 2009 Feb-Mar;32(2):129-39. doi: 10.1097/CJI.0b013e31819144d7.

20.

Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP.

Mazzucchelli R, Hixon JA, Spolski R, Chen X, Li WQ, Hall VL, Willette-Brown J, Hurwitz AA, Leonard WJ, Durum SK.

Blood. 2008 Oct 15;112(8):3283-92. doi: 10.1182/blood-2008-02-137414. Epub 2008 Jul 29.

21.

The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells.

Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA.

J Leukoc Biol. 2008 Oct;84(4):973-80. doi: 10.1189/jlb.1107778. Epub 2008 Jul 23.

22.

The TRAMP mouse as a model for prostate cancer.

Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED.

Curr Protoc Immunol. 2001 Nov;Chapter 20:Unit 20.5. doi: 10.1002/0471142735.im2005s45.

PMID:
18432778
23.

Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice.

Hu PQ, Hurwitz AA, Oppenheim JJ.

J Rheumatol. 2007 Nov;34(11):2243-52. Epub 2007 Oct 15.

PMID:
17937466
24.

T cell tolerance to tumors and cancer immunotherapy.

Shafer-Weaver K, Anderson M, Malyguine A, Hurwitz AA.

Adv Exp Med Biol. 2007;601:357-68. Review.

PMID:
17713024
25.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

27.

Augmentation of T cell levels and responses induced by androgen deprivation.

Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED.

J Immunol. 2004 Nov 15;173(10):6098-108.

28.

Autoimmune depigmentation following sensitization to melanoma antigens.

Hurwitz AA, Ji Q.

Methods Mol Med. 2004;102:421-7.

PMID:
15286398
29.

Modulation of costimulation to enhance tumor immunity.

Vesosky B, Hurwitz AA.

Cancer Immunol Immunother. 2003 Nov;52(11):663-9. Epub 2003 Aug 15. Review. No abstract available.

PMID:
12920481
30.

Prostate cancer: advances in immunotherapy.

Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED.

BioDrugs. 2003;17(2):131-8. Review.

PMID:
12641491
31.
32.
33.

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP.

J Exp Med. 2001 Aug 20;194(4):481-9.

34.

Costimulatory wars: the tumor menace.

Hurwitz AA, Kwon ED, van Elsas A.

Curr Opin Immunol. 2000 Oct;12(5):589-96. Review.

PMID:
11007364
35.

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP.

Cancer Res. 2000 May 1;60(9):2444-8.

36.

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9.

38.
39.
40.

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.

Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP.

Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103.

41.
42.

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

Allison JP, Hurwitz AA, Leach DR.

Curr Opin Immunol. 1995 Oct;7(5):682-6. Review.

PMID:
8573312
43.
44.

The role of the blood-brain barrier in HIV infection of the central nervous system.

Hurwitz AA, Berman JW, Lyman WD.

Adv Neuroimmunol. 1994;4(3):249-56. Review.

PMID:
7533041
45.

Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells.

Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD.

Brain Res. 1993 Oct 22;625(2):238-43.

PMID:
7903899
46.

Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes.

Hurwitz AA, Lyman WD, Guida MP, Calderon TM, Berman JW.

J Exp Med. 1992 Dec 1;176(6):1631-6.

47.

Cytotoxic activity of graft-infiltrating lymphocytes correlates with cellular rejection in cardiac transplant patients.

Frisman DM, Fallon JT, Hurwitz AA, Dec WG, Kurnick JT.

Hum Immunol. 1991 Dec;32(4):241-5.

PMID:
1686025
48.

Clonal analysis of graft-infiltrating lymphocytes from renal and cardiac biopsies. Dominant rearrangements of TcR beta genes and persistence of dominant rearrangements in serial biopsies.

Frisman DM, Hurwitz AA, Bennett WT, Boyle LA, Fallon JT, Dec GW, Colvin RB, Kurnick JT.

Hum Immunol. 1990 Jun;28(2):208-15.

PMID:
2141012

Supplemental Content

Loading ...
Support Center